Agios Pharmaceuticals, Inc. (AGIO)
Stock Price:
$40.55 USD
-0.53 (-1.29%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $41.44 +0.89 (2.20%) Aug 14, 6:46 PM
Key Info
| Market Cap |
2.80B |
| Revenue (ttm) |
185.91M |
| Net Income (ttm) |
-339.26M |
| Shares Out |
69.11M |
| EPS (ttm) |
-5.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$40.55 |
| Previous Close |
$41.08 |
| Change ($) |
-0.53 |
| Change (%) |
-1.29% |
| Day's Open |
41.03 |
| Day's Range |
40.38 - 41.38 |
| Day's Volume |
432,982 |
| 52-Week Range |
27.77 - 56.75 |
More Stats
| Market Cap |
2.80B |
| Enterprise Value |
2.37B |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
69.11M |
| Float |
61.26M |
| EPS (basic) |
-5.3 |
| EPS (diluted) |
-5.21 |
| FCF / Share |
-5.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.46M |
| Short Ratio |
11.41 |
| Short % of Float |
13.86% |
| Beta |
2.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.07 |
| PB Ratio |
4.99 |
| Revenue |
185.91M |
| Operating Income |
-348.38M |
| Net Income |
-339.26M |
| Free Cash Flow |
-369.91M |
| Net Cash |
429.82M |
| Net Cash / Share |
6.22 |
| Gross Margin |
-158.30% |
| Operating Margin |
-187.39% |
| Profit Margin |
-182.50% |
| FCF Margin |
-198.97% |
| ROA |
-24.74% |
| ROE |
-62.18% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (14)
| Buy |
11 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$66.83*
(64.81% upside)
Low
40.0
Current: $40.55
High
82.0
Target: 66.83
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 118 | 94.39 | 43.01 | 69.89 | 59.12 | 65.36 | 25.55 | 25.11 | 21.84 |
| Revenue Growth | 24.92% | 119.45% | -38.46% | 18.22% | -9.55% | 155.82% | 1.76% | 14.97% | - |
| Gross Profit | 117 | 92.99 | 43.01 | 69.89 | 59.12 | 65.36 | 25.55 | 25.11 | 21.84 |
| Operating Income | -426 | -362 | -321 | -201 | -119 | -54.13 | -38.88 | -23.00 | -16.63 |
| Net Income | -411 | -346 | -315 | -198 | -118 | -53.50 | -39.41 | -20.10 | -23.71 |
| Shares Outstanding | 59.99 | 57.42 | 46.59 | 39.13 | 37.43 | 33.67 | 15.42 | 3.40 | 3.01 |
| Earnings Per Share | -6.86 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.83 | -8.02 | -8.90 |
| Operating Cash Flow | -371 | -304 | -285 | 38.56 | -76.95 | -59.35 | -56.40 | -49.55 | -15.22 |
| Capital Expenditures | -12.17 | -6.99 | -4.63 | -9.92 | -20.16 | -2.22 | -1.29 | -1.48 | -1.91 |
| Free Cash Flow | -383 | -311 | -290 | 28.65 | -97.11 | -61.57 | -57.69 | -51.02 | -17.13 |
| Cash & Equivalents | 565 | 585 | 424 | 541 | 317 | 342 | 167 | 129 | 180 |
| Total Debt | 114 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 451 | 585 | 424 | 541 | 317 | 342 | 167 | 129 | 180 |
| Assets | 891 | 858 | 614 | 619 | 420 | 492 | 201 | 137 | 194 |
| Liabilities | 250 | 171 | 239 | 261 | 74.95 | 67.54 | 69.72 | 209 | 247 |
| Book Value | 641 | 688 | 376 | 359 | 345 | 424 | 131 | -72.02 | -52.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Agios Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
536 |
| CEO |
Jacqualyn A. Fouse |
Stock Information
| Ticker Symbol |
AGIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AGIO |
| IPO Date |
July 24, 2013 |
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.